Search results for "uva"

showing 10 items of 2916 documents

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients…

2003

Patients with no prior chemotherapy and with advanced and progressive follicular lymphoma (FCL) or mantle cell lymphoma (MCL) were enrolled into a treatment protocol combining CHOP/rituximab-CHOP therapy with subsequent consolidation high-dose therapy (HDT) to evaluate the safety and feasibility of this treatment. Overall, 15 patients were enrolled and 13 patients completed the entire treatment protocol without major toxicities or increased infectious complications. One patient withdrew consent after achieving complete remission (CR) prior to HDT. One patient was taken off study with signs of disease progression after induction treatment. All patients showed stable engraftment after HDT. Re…

AdultMaleOncologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellCHOPTransplantation AutologousAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideImmunosuppression TherapyPeripheral Blood Stem Cell TransplantationTransplantationChemotherapybusiness.industryGraft SurvivalRemission InductionImmunityAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurvival AnalysisNon-Hodgkin's lymphomaSurgeryLymphomaTransplantationDoxorubicinVincristineFeasibility StudiesPrednisoneFemaleRadiotherapy AdjuvantMantle cell lymphomaRituximabRituximabbusinessmedicine.drugBone Marrow Transplantation
researchProduct

The use of ketamine in a palliative-supportive care unit: a retrospective analysis.

2018

Background: To assess the response to ketamine in patients with difficult pain syndromes. Methods: The charts of patients with uncontrolled pain despite opioid dose escalation of at least two opioids or a combination of them, selected for a burst of ketamine and midazolam were reviewed. One hundred mg/day of ketamine and midazolam 15 mg/day by a continuous intravenous infusion for about 48 hours was offered to patients. Results: Forty-four patients received a burst of ketamine. Ten patients did not achieve any improvement. Pain intensity decreased from a mean of 7.8 (SD, 1.6) to 2.8 (SD, 1.3) (P<0.0005). The outcome was considered optimal, good, and mild in 24, 9, and 1 patients, respective…

AdultMalePalliative careMidazolamAdverse effect03 medical and health sciences0302 clinical medicineRetrospective analysisMedicineHumansPain ManagementKetamine030212 general & internal medicineAdverse effectRefractory painAgedRetrospective StudiesAdvanced and Specialized NursingAged 80 and overbusiness.industryPalliative CareRetrospective cohort studyCancer PainMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidChemotherapy AdjuvantAnesthesiaMidazolamFemaleKetaminebusinessCancer pain030217 neurology & neurosurgerymedicine.drugAnnals of palliative medicine
researchProduct

Management of head and neck paragangliomas: review of 120 patients.

2008

Head and neck paragangliomas (PGL) are rare, mostly benign tumors. About 10% to 15% of PGL are caused by mutations in the succinate dehydrogenase genes B, C, or D and may appear multifocally.A retrospective review of 120 patients with 146 head and neck PGL, including 46 carotid body tumors (CBT), 13 vagal tumors, 55 jugulotympanic tumors (JTT), 25 tympanic tumors (TT) and 7 tumors in other locations are included. The internal carotid artery was preserved in 97.5% of CBT resections. Preservation of hearing was achieved in 92% of JTT and 88% of TT resections.According to our experience, the treatment of PGL must be individualized, taking into account the patient's age, medical condition, tumo…

AdultMalePathologymedicine.medical_specialtyAdolescentCarotid arteriesmedicine.medical_treatmentOutcome assessmentDeafnessParagangliomaYoung AdultNeoplasm RecurrencePostoperative ComplicationsParagangliomaOutcome Assessment Health CaremedicineHumansEmbolizationHead and neckChildAgedRetrospective StudiesAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseEmbolization TherapeuticCranial Nerve DiseasesRadiation therapyOtorhinolaryngologyHead and Neck NeoplasmsFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCarotid Artery InternalHeadneck
researchProduct

Testicular fusocellular rhabdomyosarcoma as a metastasis of elbow sclerosing rhabdomyosarcoma: A clinicopathologic, immunohistochemical and molecular…

2010

Abstract Sclerosing rhabdomyosarcoma (SRMS) is an infrequent variant of rhabdomyosarcoma characterized by extensive intercellular hyaline fibrosis. We report the case of a 37 year-old male with a 9 × 6 cm SRMS on the right elbow. Histologically, the tumor showed an abundant extracellular hyaline matrix with extratumoral vascular emboli and microscopic foci of fusocellular embryonal rhabdomyosarcoma (FRMS) separated by a fibrotic band from the sclerosing areas. One year later the patient presented with a right intratesticular tumor of 1.2 × 0.8 cm, which was reported as pure FRMS. Immunohistochemically, SRMS was positive only for MyoD1 and Vimentin and negative for Myogenin and Desmin. Both …

AdultMalePathologymedicine.medical_specialtyHistologyTime FactorsVimentinCase ReportSoft Tissue NeoplasmsSclerosing rhabdomyosarcomaBiologyTranslocation GeneticPathology and Forensic MedicineMetastasisFatal OutcomeTesticular Neoplasmslcsh:PathologymedicineBiomarkers TumorElbowHumansRhabdomyosarcoma EmbryonalWhole Body ImagingRhabdomyosarcomaHyalineIn Situ Hybridization FluorescenceSclerosisChromosomes Human Pair 13Forkhead Box Protein O1MediastinumForkhead Transcription FactorsGeneral Medicinemedicine.diseasemusculoskeletal systemFibrosisImmunohistochemistrymedicine.anatomical_structureTreatment OutcomeChemotherapy Adjuvantbiology.proteinDesminEmbryonal rhabdomyosarcomaTomography X-Ray ComputedOrchiectomylcsh:RB1-214
researchProduct

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccinatio…

2009

Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adu…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross Protectionmedicine.medical_treatmentPopulationImmunization SecondaryBooster doseAntibodies ViralYoung AdultAdjuvants ImmunologicImmunityInfluenza Humanparasitic diseasesmedicineHumansAS03educationeducation.field_of_studyBooster (rocketry)Influenza A Virus H5N1 SubtypeGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthHemagglutination Inhibition TestsMiddle AgedImmunity HumoralVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

2014

ABSTRACT Background At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. Patients and methods Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9–241 months). Ex…

AdultMalePrognosiHydro-Lyasemedicine.medical_treatmentSarcoma EwingDisease-Free SurvivalCyclin D1medicineHumansCyclin D1Neoplasm Metastasisprognostic biomarkerNeoadjuvant therapyHydro-LyasesAged 80 and overTissue microarraybiologybusiness.industryProportional hazards modelMedicine (all)Ewing's sarcomaMicroRNAHematologyMiddle Agedmedicine.diseasePrognosisNeoadjuvant TherapyNeoplasm MetastasiGene Expression Regulation NeoplasticMicroRNAsKi-67 AntigenTreatment OutcomeOncologyDrug Resistance NeoplasmKi-67biology.proteinCancer researchKi-67ImmunohistochemistryFemaleSarcomacyclin D1; Ewing sarcoma; Ki-67; miR-34a; prognostic biomarkers; Adult; Aged 80 and over; Cyclin D1; Disease-Free Survival; Drug Resistance Neoplasm; Female; Gene Expression Regulation Neoplastic; Humans; Hydro-Lyases; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Sarcoma Ewing; Treatment Outcome; Medicine (all)businessEwing sarcomamiR-34aHumanAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct

Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma

2013

Objective: The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of immunotherapy contributes to asthma control. Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered, before the pollen season, to 20 Parietaria-sensitive mild, untreated asthmatics (M/F: 12/8; age: 38 ± 14 years). After the screening visit (visit 1), asthma control was assessed by the Asthma Control Test (ACT) immediately before the fi…

AdultMalePulmonary and Respiratory MedicineBreath TestParietariamedicine.drug_classmedicine.medical_treatmentMonophosphoryl Lipid Aairway inflammationSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideAnti-inflammatoryAllergic symptomsmedicineHumansPharmacology (medical)LungAsthmaInflammationVaccinesbiologybusiness.industryAllergy vaccineImmunotherapyMiddle Agedmedicine.diseasebiology.organism_classificationAsthmaParietariaquality of lifeBreath TestsDesensitization ImmunologicImmunologyFemaleimmunotherapybusinessVaccineAdjuvantHumanTherapeutic Advances in Respiratory Disease
researchProduct

The Influence of the Primary Tumor on the Long-term Results of Pulmonary Metastasectomy for Metastatic Renal Cell Carcinoma

2011

OBJECTIVE To investigate one of the primary tumor (PT) on pulmonary metastasectomy (PM) for metastatic renal cell carcinoma (RCC) and to define prognostic factors. METHODS Retrospective review of patients with pulmonary metastases from RCC from January 1999 through December 2008 was performed. All patients underwent PM with curative intend. TNM-classification, tumor stage and PT grade, disease-free-interval (DFI) from nephrectomy to the diagnosis of metastasis, systemic chemotherapy before surgical intervention, surgical procedures, morbidity, mortality, and survival were investigated. RESULTS One-hundred seven consecutive patients (age 61.5 ± 9.6 years) underwent PM. Morbidity and mortalit…

AdultMalePulmonary and Respiratory MedicineOncologymedicine.medical_specialtyLung NeoplasmsTime Factorsmedicine.medical_treatmentUrologyKaplan-Meier EstimateNephrectomyRisk AssessmentRisk FactorsRenal cell carcinomaInternal medicinemedicineAdjuvant therapyHumansPneumonectomyCarcinoma Renal CellAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overUnivariate analysisProportional hazards modelbusiness.industryMortality rateMetastasectomyMiddle Agedmedicine.diseasePrimary tumorKidney NeoplasmsNeoadjuvant TherapyNephrectomyTreatment OutcomeChemotherapy AdjuvantLymphatic MetastasisMultivariate AnalysisFemaleSurgeryNeoplasm GradingMetastasectomyCardiology and Cardiovascular MedicinebusinessThe Thoracic and Cardiovascular Surgeon
researchProduct

pT2 Adenocarcinoma of the Esophagus: Early or Advanced Cancer?

2013

Background There is an increasing trend to include patients with esophageal carcinoma invading the muscularis propria (pT2) in neoadjuvant therapy regimens. But it is unclear which patients have prognostic benefit from this strategy. The aim of this study was to assess the prognosis and prognostic factors in patients with pT2 esophageal adenocarcinoma to further optimize treatment strategies. Methods Included were patients with pT2 esophageal adenocarcinoma treated operatively at three centers specializing in upper gastrointestinal surgery. There were 159 patients (139 male) without induction therapy; median age was 64.5 years. Survival was analyzed by univariate and multivariate analysis. …

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaGastroenterologyInternal medicinemedicineCarcinomaHumansEsophagusLymph nodeSurvival rateNeoadjuvant therapyAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryHazard ratioMiddle AgedPrognosismedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureLymphatic MetastasisAdenocarcinomaFemaleSurgeryLymphCardiology and Cardiovascular MedicinebusinessThe Annals of Thoracic Surgery
researchProduct